Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3JN6C
|
|||
| Drug Name |
GRN 1201
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2] | ||
| Company |
GreenPeptide
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03417882) GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02696356) Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.